scholarly journals Immunotherapy in Gynecologic Cancers

10.5772/67605 ◽  
2017 ◽  
Author(s):  
Marcus Vetter ◽  
Viola Heinzelmann-Schwarz
Keyword(s):  
Gynecologic Cancers

Other gynecologic cancers

2003 ◽  
Author(s):  
Eliane Duarte-Franco ◽  
Eduardo L. Franco
Keyword(s):  
Gynecologic Cancers

Non-gynecologic cancers in pregnant women

2018 ◽  
Vol 16 (2) ◽  
pp. 126-136
Author(s):  
Aleksandra Stupak ◽  
◽  
Anna Kwaśniewska ◽  
Keyword(s):  
Pregnant Women ◽  
Gynecologic Cancers

Serum HE4 Level as a Biomarker to Predict the Recurrence of Gynecologic Cancers

2017 ◽  
Vol 18 (10) ◽  
Author(s):  
Jinping Li ◽  
Haibin Chen ◽  
John R. Curcuru ◽  
Sheena Patel ◽  
Taylor O. Johns ◽  
...  
Keyword(s):  
Gynecologic Cancers

Gynecologic Cancers in Pregnancy

2009 ◽  
Vol 19 (Suppl 1) ◽  
pp. S1-S12 ◽  
Author(s):  
Frédéric Amant ◽  
Kristel Van Calsteren ◽  
Michael J. Halaska ◽  
Jos Beijnen ◽  
Lieven Lagae ◽  
...  
Keyword(s):  
Gynecologic Cancers ◽  
In Pregnancy

scholarly journals Development and Carcinogenesis: Roles of GATA Factors in the Sympathoadrenal and Urogenital Systems

Biomedicines ◽  
2021 ◽  
Vol 9 (3) ◽  
pp. 299
Author(s):  
Takashi Moriguchi
Keyword(s):  
Transcription Factors ◽  
Developmental Process ◽  
Current Knowledge ◽  
Gynecologic Cancers ◽  
Inherited Diseases ◽  
Gata Factors ◽  
Transcriptional Regulatory ◽  
Gata Family

The GATA family of transcription factors consists of six proteins (GATA1-6) that control a variety of physiological and pathological processes. In particular, GATA2 and GATA3 are coexpressed in a number of tissues, including in the urogenital and sympathoadrenal systems, in which both factors participate in the developmental process and tissue maintenance. Furthermore, accumulating studies have demonstrated that GATA2 and GATA3 are involved in distinct types of inherited diseases as well as carcinogenesis in diverse tissues. This review summarizes our current knowledge of how GATA2 and GATA3 participate in the transcriptional regulatory circuitry during the development of the sympathoadrenal and urogenital systems, and how their dysregulation results in the carcinogenesis of neuroblastoma, renal urothelial, and gynecologic cancers.

PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?

2020 ◽  
Vol 22 (3) ◽  
Author(s):  
Michelle Lightfoot ◽  
Lauren Montemorano ◽  
Kristin Bixel
Keyword(s):  
Parp Inhibitors ◽  
Gynecologic Cancers

Primary prevention of gynecologic cancers

1995 ◽  
Vol 172 (1) ◽  
pp. 227-235 ◽  
Author(s):  
David A. Grimes ◽  
Katherine E. Economy
Keyword(s):  
Primary Prevention ◽  
Gynecologic Cancers
Sign in / Sign up

Export Citation Format

Share Document